Sign in
WithdrawnNo phase

U.S. Multicenter Feasibility Trial of the F2 Filter and Delivery System for Embolic Protection During TAVR

Key facts

Who runs it
EnCompass Technologies, Inc.
Where
New York, United StatesSee the site
Trial code
Status
Withdrawn
Started
Jun 2024
Ended
Jan 2025
Type of study
Interventional
Treatments tested
  • Aortic Stenosis
Record updated
25 February 2025
Why it stopped
moving directly into the Pivotal study

Who can take part

Age
22 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 31 criteriaShow less

Who can take part

  • Age ≥ 22 years
  • The patient meets the established criteria and indications for commercially available TAVR (Edwards/Medtronic) for transfemoral access
  • Modified Rankin Scale (mRS) 0 or 1 at screening
  • Montreal Cognitive Assessment (MoCA) score ≥ 26 at screening
  • The patient is willing and able to comply with protocol-specified follow-up evaluations; 6 The patient or legally authorized representative is able and willing to provide written informed consent

Who cannot take part

  • Contraindications to MRI (e.g., subjects with MR unsafe implants including implantable temporary or permanent pacemaker or defibrillator, metal implants in field of view, metallic fragments, clips, or devices in the brain or eye before TAVR procedure, or claustrophobia)
  • Evidence of an acute myocardial infarction within 1 month before TAVR
  • Active peptic ulcer or history of upper gastrointestinal (GI) bleeding within the prior 3 months
  • Currently participating in an investigational drug or another device study that has not completed the initial primary endpoint evaluation (e.g., long term follow-up study/continued access study subjects are able to be included)
  • Subjects who have had treatment with any other investigational device within 30 days prior to study enrollment
  • Planned surgery or invasive procedure within 30 days following the index procedure (TAVR with F2 Filter)
  • Patients planned to undergo any other cardiac surgical or interventional procedure (e.g., concurrent coronary revascularization) during the TAVR procedure or within 10 days prior to the TAVR procedure. NOTE: Balloon valvuloplasty during TAVR is permitted. Diagnostic cardiac catheterization is permitted within 10 days prior to the TAVR procedure
  • Severe peripheral arterial, abdominal aortic, or thoracic aortic disease that precludes delivery sheath vascular access or filter deployment
  • Pre-existing prosthetic heart valve or prosthetic ring in any position
  • Severe allergy or known hypersensitivity or contraindication to aspirin, heparin/bivalirudin, clopidogrel, nitinol, stainless steel alloy, and/or contrast sensitivity that cannot be adequately pre-medicated
  • Patients with hepatic failure (Child-Pugh class C)
  • Patients with known mental or physical illness or known history of substance abuse that may cause non-compliance with the protocol or confound the data interpretation
  • Any other condition that in the opinion of the investigator, precludes study participation or poses a significant hazard to the patient
  • History of bleeding diathesis or coagulopathy or patients in whom anti-platelet and/or anticoagulant therapy is contraindicated
  • Renal insufficiency (creatinine > 2.5 mg/dL or GFR < 30) and/or renal replacement therapy at the time of screening
  • Severe ventricular dysfunction with left ventricular ejection fraction (LVEF) < 20%
  • Subjects are not eligible for the study if any of the following criteria are present:
  • Patients in whom the aortic arch is heavily calcified, severely atheromatous, or severely tortuous
  • Ascending aortic diameter > 38 mm or transverse aortic diameter > 27 mm
  • Known intracardiac thrombus
  • Patients who refuse blood transfusion
  • Recent (within 6 months) CVA or a TIA
  • Patients with hypercoagulable states that cannot be corrected by additional periprocedural heparin
  • Patients presenting with cardiogenic shock or requiring vasopressor or inotropic support at the time of the index procedure
  • Life expectancy < 12 months
  • Females who are pregnant or nursing or plan to become pregnant during their participation in the study. Female subjects of child-bearing potential must have a negative pregnancy test at screening

Where in United States

  • New York Presbyterian - Columbia UniversityNew York, United States

About the trial

What the trial wants to find out

The goal of this clinical trial is to learn about the safety and performance of the F2 device for cerebral embolic protection in participants with symptomatic aortic stenosis undergoing a Transcatheter Aortic Valve replacement procedure.

The group in the trial

  • Single-ArmTreatment being tested

    Device: F2 Filter and Delivery System

    Treatment: Aortic Stenosis

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Prospective, Single-arm, Multicenter Feasibility Trial to Evaluate the Safety and Performance of the F2 Filter and Delivery System Used for Embolic Protection During Transcatheter Aortic Valve Replacement
Record updated
25 February 2025